Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,225 Million (Small Cap)
28.00
NA
0.00%
6.58
601.76%
140.08
Revenue and Profits:
Net Sales:
86 Million
(Quarterly Results - Sep 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.09%
0%
-10.09%
6 Months
14.72%
0%
14.72%
1 Year
59.91%
0%
59.91%
2 Years
345.45%
0%
345.45%
3 Years
110.43%
0%
110.43%
4 Years
76.8%
0%
76.8%
5 Years
66.1%
0%
66.1%
Hunan Jingfeng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-20.31%
EBIT Growth (5y)
14.30%
EBIT to Interest (avg)
-1.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
5.50
Sales to Capital Employed (avg)
1.00
Tax Ratio
3.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.30%
ROE (avg)
44.62%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
83.55
EV to EBIT
-140.26
EV to EBITDA
-777.52
EV to Capital Employed
9.99
EV to Sales
11.70
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
-7.12%
ROE (Latest)
303.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
86.30
81.40
6.02%
Operating Profit (PBDIT) excl Other Income
0.30
-4.40
106.82%
Interest
0.00
7.80
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.10
-21.00
47.14%
Operating Profit Margin (Excl OI)
3.20%
-134.20%
13.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 6.02% vs -17.61% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 47.14% vs -87.50% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
412.40
650.50
-36.60%
Operating Profit (PBDIT) excl Other Income
11.10
-56.90
119.51%
Interest
40.40
42.00
-3.81%
Exceptional Items
238.80
-64.00
473.12%
Consolidate Net Profit
159.40
-227.50
170.07%
Operating Profit Margin (Excl OI)
-43.80%
-159.80%
11.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -36.60% vs -21.47% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 170.07% vs -138.72% in Dec 2023
About Hunan Jingfeng Pharmaceutical Co., Ltd. 
Hunan Jingfeng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






